| scholarly article | Q13442814 |
| P50 | author | Meliha C Kapetanovic | Q58327277 |
| Lennart T. H. Jacobsson | Q110625350 | ||
| P2093 | author name string | Carl Turesson | |
| Pierre Geborek | |||
| Tore Saxne | |||
| Ingemar F Petersson | |||
| Anders Gülfe | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 1213-1218 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | The Journal of Rheumatology | Q7743623 |
| P1476 | title | Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis | |
| P478 | volume | 32 |
| Q34027648 | 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis |
| Q36434758 | A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1 |
| Q33687843 | Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis |
| Q37866627 | Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets |
| Q38238948 | Adverse reactions to biologic agents and their medical management. |
| Q64123686 | An Observational Study of Cardiovascular Risks Associated with Rheumatoid Arthritis Therapies: A Comparison of Two Analytical Approaches |
| Q26997311 | Anti-TNF therapy: past, present and future |
| Q34348277 | Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a pilot study. |
| Q37626768 | Anti-inflammatory therapeutics for the treatment of atherosclerosis |
| Q38349757 | Anti-inflammatory therapies for atherosclerosis |
| Q36246116 | Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance |
| Q36633289 | Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. |
| Q35599025 | Association between anti-TNF therapy for rheumatoid arthritis and hypertension: a meta-analysis of randomized controlled trials |
| Q36590690 | Association between anti-TNF-α therapy and all-cause mortality |
| Q36596894 | Atherogenic lipid profiles and its management in patients with rheumatoid arthritis |
| Q38993250 | Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. |
| Q24568196 | Biologics, cardiovascular effects and cancer |
| Q92462247 | Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis |
| Q36528304 | Blood pressure and TNF-α act synergistically to increase leucocyte CD11b adhesion molecule expression in the BELFAST study: implications for better blood pressure control in ageing |
| Q37145684 | Cardiometabolic risk in psoriasis: differential effects of biologic agents |
| Q54255528 | Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients. |
| Q88917533 | Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis |
| Q35557796 | Cardiovascular co-morbidity in patients with rheumatic diseases. |
| Q36835851 | Cardiovascular co-morbidity in rheumatic diseases |
| Q33943374 | Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment |
| Q36757060 | Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study |
| Q38260198 | Cardiovascular risk and the use of biologic agents in rheumatoid arthritis |
| Q36361147 | Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs |
| Q30426026 | Coronary Artery Disease Evaluation in Rheumatoid Arthritis (CADERA): study protocol for a randomized controlled trial |
| Q93031598 | Coronary artery disease is associated with an altered gut microbiome composition |
| Q92733573 | Could Omega 3 Fatty Acids Preserve Muscle Health in Rheumatoid Arthritis? |
| Q93250708 | Covid-19 treatment update: follow the scientific evidence |
| Q35093040 | Decrease in the incidence of total hip arthroplasties in patients with rheumatoid arthritis--results from a well defined population in south Sweden |
| Q37207010 | Developments in the clinical understanding of rheumatoid arthritis |
| Q37892915 | Diabetic microvascular complications: possible targets for improved macrovascular outcomes |
| Q34058462 | Endothelial progenitor cells in arthritis-associated vasculogenesis and atherosclerosis. |
| Q59684000 | Evaluation of Ascending Aorta Wall in Rheumatoid Arthritis by Tissue and Strain Doppler Imaging During Anti-Tumor Necrosis Factor-α Therapy |
| Q51244473 | Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease. |
| Q42370776 | Genetic variation associated with cardiovascular risk in autoimmune diseases |
| Q33582240 | HVC1 ameliorates hyperlipidemia and inflammation in LDLR-/- mice |
| Q88226754 | IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood |
| Q38927961 | Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes |
| Q79610823 | Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis |
| Q37060522 | Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction |
| Q56337838 | Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty |
| Q39360950 | Inflammation and atherosclerosis: disease modulating therapies |
| Q37245192 | Infliximab improves vascular stiffness in patients with rheumatoid arthritis |
| Q34346418 | Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months |
| Q35152141 | Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis |
| Q28547208 | Long-term frequent use of non-steroidal anti-inflammatory drugs might protect patients with ankylosing spondylitis from cardiovascular diseases: a nationwide case-control study |
| Q37358124 | Long-term use of adalimumab in the treatment of rheumatic diseases. |
| Q37428743 | Management of cardiovascular disease risk in chronic inflammatory disorders |
| Q37975943 | Managing cardiovascular risk in patients with chronic inflammatory diseases. |
| Q38271745 | Metabolic syndrome and chronic arthritis: effects of anti-TNF-α therapy |
| Q36204149 | Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis |
| Q34699641 | No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register |
| Q33779130 | Observational studies: a valuable source for data on the true value of RA therapies |
| Q36955351 | Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project |
| Q53502883 | Prevention of stroke in rheumatoid arthritis. |
| Q38608511 | Progression rate of severity of aortic stenosis in patients with rheumatoid arthritis |
| Q36633243 | Prothrombotic effects of tumor necrosis factor alpha in vivo are amplified by the absence of TNF-alpha receptor subtype 1 and require TNF-alpha receptor subtype 2. |
| Q37449514 | Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study |
| Q36732112 | Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register |
| Q47314271 | Regulation of pro- and anti-atherogenic cytokines |
| Q45669904 | Relationship between inflammatory markers, oxidant-antioxidant status and intima-media thickness in prepubertal children with juvenile idiopathic arthritis |
| Q37632485 | Relationship between tumor necrosis factor-α inhibitors and cardiovascular disease in psoriasis: a review |
| Q37988317 | Rheumatoid arthritis and the era of biologic therapy |
| Q37472928 | Role for TNF in atherosclerosis? Lessons from autoimmune disease |
| Q36968832 | Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus |
| Q35637262 | Swedish registers to examine drug safety and clinical issues in RA. |
| Q37801353 | Systematic review and meta‐analysis: Anti–tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis |
| Q35154761 | Systemic inflammation and early atheroma formation: are they related? |
| Q36057159 | T cell immunity and cardiovascular metabolic disorders: does metabolism fuel inflammation? |
| Q83844887 | Tc-99m sestamibi lower extremity muscle scan, is it a useful screening tool for assessment of preclinical atherosclerosis in rheumatoid arthritis patients? |
| Q41248114 | The Assessment of Subclinical Cardiovascular Dysfunction in Treated Rheumatoid Arthritis |
| Q39028288 | The Role of Cytokines in the Development of Atherosclerosis |
| Q33838927 | The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis |
| Q33848290 | The effect of anti-rheumatic medications for coronary artery diseases risk in patients with rheumatoid arthritis might be changed over time: A nationwide population-based cohort study. |
| Q37427394 | The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis |
| Q35135831 | The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. |
| Q39230390 | The immunology of atherosclerosis |
| Q35092457 | The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. |
| Q35230117 | The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients |
| Q37206876 | The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus |
| Q58727105 | The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor α in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis |
| Q33892790 | The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study |
| Q35953268 | Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis |
| Q36148660 | Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis |
| Q28219857 | Tumor necrosis factor alpha and adalimumab differentially regulate CD36 expression in human monocytes |
| Q37580905 | Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety |
| Q37851001 | Unresolved issues in biologic therapy for rheumatoid arthritis |
| Q34818636 | Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials |
| Q34592673 | Update on the treatment of ankylosing spondylitis |
| Q37630351 | Vascular effects of biologic agents in RA and spondyloarthropathies |
| Q35954625 | What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. |
| Q84815164 | [Cardiovascular comorbidity and its risk factors in rheumatoid arthritis] |
| Q83200986 | [Co-morbidities in psoriasis vulgaris] |
| Q81141986 | [Infliximab. Role in the treatment of psoriasis] |
| Q80314055 | [Rheumatoid arthritis and cardiovascular complications] |
| Q85589116 | [Risk of atherosclerosis mediated by inflammation in rheumatoid arthritis] |
| Q85055006 | [Strategies for improved healthcare of people with the endemic disease rheumatism exemplified by rheumatoid arthritis] |
Search more.